Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of xevinapant plus postoperative IMRT versus placebo plus IMRT in resected high-risk head and neck squamous cell carcinoma unsuitable for high-dose cisplatin
MOH_2023-06-18_012747Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Xevinapant + IMRT with Placebo + IMRT (2 arms). Primary endpoint: Disease-free survival. Started Feb 2023; status: completed.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2023-06-18_012747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-18_012747.